دورية أكاديمية
Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status.
العنوان: | Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status. |
---|---|
المؤلفون: | Rossing M; Center for Genomic Medicine 4113, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark. caroline.maria.rossing@regionh.dk., Pedersen CB; Center for Genomic Medicine 4113, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.; Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark., Tvedskov T; Department of Breast Surgery, Rigshospitalet/Herlev-Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark., Vejborg I; Department of Radiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Talman ML; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Olsen LR; Center for Genomic Medicine 4113, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.; Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark., Kroman N; Department of Breast Surgery, Rigshospitalet/Herlev-Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark., Nielsen FC; Center for Genomic Medicine 4113, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark., Jensen MB; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Ejlertsen B; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. |
المصدر: | Scientific reports [Sci Rep] 2021 Jan 26; Vol. 11 (1), pp. 2259. Date of Electronic Publication: 2021 Jan 26. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: London : Nature Publishing Group, copyright 2011- |
مواضيع طبية MeSH: | Breast Neoplasms/*classification , Breast Neoplasms/*pathology , Sentinel Lymph Node/*pathology, BRCA1 Protein/metabolism ; BRCA2 Protein/metabolism ; Breast Neoplasms/metabolism ; Cohort Studies ; Female ; Humans ; Logistic Models ; Menopause ; Principal Component Analysis ; Receptors, Estrogen/metabolism ; Survival Analysis ; Tumor Burden |
مستخلص: | Axillary lymph node status is an important prognostic factor for breast cancer patients and sentinel lymph node biopsy (SLNB) is a less invasive surgical proxy. We examined if consecutively derived molecular subtypes from primary breast cancers provide additional predictive value for SLNB status. 1556 patients with a breast cancer > 10 mm underwent primary surgical procedure including SLNB and tumor specimens were assigned with a transcriptomics-based molecular subtype. 1020 patients had a negative sentinel node (SN) and 536 a positive. A significant association between tumor size and SN status (p < 0.0001) was found across all samples, but no association between size and SN status (p = 0.14) was found for BasL tumors. A BasL subtype was a predictor of an SN-negative status (p = 0.001, OR 0.58, 95% CI 0.38;0.90) and among the BasL, postmenopausal status was a predictor for SN-negative status (p = 0.01). Overall survival was significantly lower (p = 0.02) in patients with BasL tumors and a positive SN. Interestingly, we identified a significant correlation between hormone receptor activity and SN status within the BasL subtype. Taken together, molecular subtypes and hormone receptor activity of breast cancers add predictive value for SLNB status. |
References: | Acta Oncol. 2018 Jan;57(1):58-66. (PMID: 29164972) BMC Cancer. 2015 Mar 19;15:151. (PMID: 25885340) Biostatistics. 2007 Jan;8(1):118-27. (PMID: 16632515) Nucleic Acids Res. 2005 Nov 10;33(20):e175. (PMID: 16284200) Oncotarget. 2017 Feb 2;8(33):55534-55543. (PMID: 28903439) NPJ Breast Cancer. 2020 Mar 6;6:8. (PMID: 32195331) Breast Cancer Res Treat. 2009 Jan;113(1):181-7. (PMID: 18264760) N Engl J Med. 2017 Nov 9;377(19):1836-1846. (PMID: 29117498) Breast Cancer Res Treat. 2016 Jan;155(2):215-22. (PMID: 26740214) Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6994-9. (PMID: 20335537) Int J Surg. 2015 Sep;21:156-61. (PMID: 26253849) Am J Surg. 2001 Oct;182(4):316-20. (PMID: 11720662) Lancet Oncol. 2010 Oct;11(10):927-33. (PMID: 20863759) Bioinformatics. 2012 Mar 15;28(6):882-3. (PMID: 22257669) Eur J Surg Oncol. 2012 Dec;38(12):1211-7. (PMID: 22954526) Cancer. 2005 Feb 1;103(3):492-500. (PMID: 15612028) Ann Surg. 2007 Mar;245(3):452-61. (PMID: 17435553) Nature. 2002 Jan 31;415(6871):530-6. (PMID: 11823860) Oncol Lett. 2019 Feb;17(2):1986-1995. (PMID: 30675265) Breast Cancer Res Treat. 2012 Aug;135(1):301-6. (PMID: 22752290) Bioinformatics. 2004 Feb 12;20(3):307-15. (PMID: 14960456) Ann Surg Oncol. 2012 Feb;19(2):567-76. (PMID: 21792511) Oncogene. 2012 Mar 1;31(9):1196-206. (PMID: 21785460) Nature. 2000 Aug 17;406(6797):747-52. (PMID: 10963602) Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792) J Clin Oncol. 2009 Mar 10;27(8):1160-7. (PMID: 19204204) Breast. 2020 Jun;51:40-49. (PMID: 32200207) Lancet Oncol. 2018 Nov;19(11):1516-1529. (PMID: 30337220) N Engl J Med. 2003 Aug 7;349(6):546-53. (PMID: 12904519) Breast Cancer Res Treat. 2008 Mar;108(2):191-201. (PMID: 18297396) N Engl J Med. 2010 Nov 11;363(20):1938-48. (PMID: 21067385) Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517) Clin Breast Cancer. 2008 Jun;8(3):249-56. (PMID: 18650155) Breast. 2015 Nov;24 Suppl 2:S26-35. (PMID: 26253814) Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. (PMID: 11553815) Breast Cancer Res. 2007;9(1):R4. (PMID: 17217540) PLoS One. 2011;6(5):e20297. (PMID: 21655258) BMC Cancer. 2019 Jan 10;19(1):45. (PMID: 30630443) APMIS. 2012 Apr;120(4):341-7. (PMID: 22429216) Oncogene. 2006 Mar 2;25(9):1413-9. (PMID: 16261164) Breast Cancer Res Treat. 2015 Jan;149(1):229-36. (PMID: 25488719) Ann Surg Oncol. 2014 Jul;21(7):2229-36. (PMID: 24664623) Oncogene. 2006 Jun 29;25(28):3994-4008. (PMID: 16491124) Nature. 2012 Apr 18;486(7403):346-52. (PMID: 22522925) |
المشرفين على المادة: | 0 (BRCA1 Protein) 0 (BRCA2 Protein) 0 (Receptors, Estrogen) |
تواريخ الأحداث: | Date Created: 20210127 Date Completed: 20210915 Latest Revision: 20210915 |
رمز التحديث: | 20221213 |
مُعرف محوري في PubMed: | PMC7838175 |
DOI: | 10.1038/s41598-021-81538-4 |
PMID: | 33500440 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2045-2322 |
---|---|
DOI: | 10.1038/s41598-021-81538-4 |